AU5876899A - Polymorphisms in the human alpha4 integrin subunit gene, suitable for diagnosis and treatment of integrin ligand mediated diseases - Google Patents

Polymorphisms in the human alpha4 integrin subunit gene, suitable for diagnosis and treatment of integrin ligand mediated diseases

Info

Publication number
AU5876899A
AU5876899A AU58768/99A AU5876899A AU5876899A AU 5876899 A AU5876899 A AU 5876899A AU 58768/99 A AU58768/99 A AU 58768/99A AU 5876899 A AU5876899 A AU 5876899A AU 5876899 A AU5876899 A AU 5876899A
Authority
AU
Australia
Prior art keywords
polymorphisms
diagnosis
integrin
treatment
mediated diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU58768/99A
Other languages
English (en)
Inventor
John Edward Norris Morten
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
Zeneca Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9820339.1A external-priority patent/GB9820339D0/en
Priority claimed from GBGB9824506.1A external-priority patent/GB9824506D0/en
Application filed by Zeneca Ltd filed Critical Zeneca Ltd
Publication of AU5876899A publication Critical patent/AU5876899A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C12Q1/683—Hybridisation assays for detection of mutation or polymorphism involving restriction enzymes, e.g. restriction fragment length polymorphism [RFLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pathology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
AU58768/99A 1998-09-19 1999-09-15 Polymorphisms in the human alpha4 integrin subunit gene, suitable for diagnosis and treatment of integrin ligand mediated diseases Abandoned AU5876899A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB9820339 1998-09-19
GBGB9820339.1A GB9820339D0 (en) 1998-09-19 1998-09-19 Chemical compounds
GBGB9824506.1A GB9824506D0 (en) 1998-11-10 1998-11-10 Chemical compounds
GB9824506 1998-11-10
PCT/GB1999/003071 WO2000017394A1 (fr) 1998-09-19 1999-09-15 Polymorphismes du gene humain de la sous-unite alpha 4 de l'integrine, appropries au diagnostic et au traitement des maladies mediees par un ligand d'integrine

Publications (1)

Publication Number Publication Date
AU5876899A true AU5876899A (en) 2000-04-10

Family

ID=26314385

Family Applications (1)

Application Number Title Priority Date Filing Date
AU58768/99A Abandoned AU5876899A (en) 1998-09-19 1999-09-15 Polymorphisms in the human alpha4 integrin subunit gene, suitable for diagnosis and treatment of integrin ligand mediated diseases

Country Status (4)

Country Link
EP (1) EP1112381A1 (fr)
JP (1) JP2002526091A (fr)
AU (1) AU5876899A (fr)
WO (1) WO2000017394A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10019058A1 (de) * 2000-04-06 2001-12-20 Epigenomics Ag Detektion von Variationen des DNA-Methylierungsprofils
DK1384777T3 (da) * 2001-03-30 2009-09-07 Shunichi Shiozawa Genom-DNA deltagende i rheumatoid arthitis, fremgangsm de til diagnosticering af det samme, fremgangsm de til at vurdere begyndelsesrisiko og diagnostisk kit til at detektere det samme
US8133859B2 (en) 2006-09-27 2012-03-13 The United States Of America As Represented By The Department Of Health And Human Services SCGB3A2 as a growth factor and anti-apoptotic agent
GB2466025A (en) * 2008-12-08 2010-06-09 Univ Francois Rabelais De Tour C3/ITGAM polymorphisms and cancer prognosis
CN103619874A (zh) 2011-06-30 2014-03-05 株式会社免疫生物研究所 可溶性整联蛋白α4突变体

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK162890D0 (da) * 1990-07-06 1990-07-06 Novo Nordisk As Polypeptid
EP0897567A2 (fr) * 1996-04-19 1999-02-24 Spectra Biomedical, Inc. Formes polymorphes en correlation au niveau de phenotypes multiples

Also Published As

Publication number Publication date
JP2002526091A (ja) 2002-08-20
WO2000017394A1 (fr) 2000-03-30
EP1112381A1 (fr) 2001-07-04

Similar Documents

Publication Publication Date Title
AU2002255248A1 (en) Diagnosis, treatment and research of mental disorders
GB9903841D0 (en) Diagnosis and treatment of cancer
HK1033278A1 (en) Pharmaceutical preparation for use in anti-asthma therapy.
PL346904A1 (en) Pharmaceutical agents for the treatment of parkinson's disease, adhd and microadenomas
AU7896100A (en) Selective estrogen receptor modulators in the treatment or reduction of the riskof acquiring hypertension, cardiovascular diseases, and insulin resistance
AU5215300A (en) Dental treatment area
ZA97741B (en) Pharmaceutical combined preparation and its use in the treatment of gynaecological disorders.
AU7748200A (en) Hypoxia-related human genes, proteins, and uses thereof
AU6425800A (en) Agents for the diagnosis, prognosis and treatment of malignant diseases
HUP0201997A3 (en) Polymorphisms in the human mdr-1 gene and their use in diagnostic and therapeutic applications
AU6583700A (en) Proteins, genes and their use for diagnosis and treatment of breast cancer
EP0676200A3 (fr) Utilisation de l'éliprodil et de ses énantiomères pour la préparation de médicaments utiles dans le traitement des neuropathies périphériques et des maladies neurodégénératives centrales.
AU2729400A (en) Application of a viral complement inhibitory protein in the treatment and diagnosis of alzheimer's disease
AU1101901A (en) Human fgf-20 gene and gene expression products
AU3593599A (en) Drugs for reducing vaginal acidity and treatment of vaginitis, and the use thereof
AU5876899A (en) Polymorphisms in the human alpha4 integrin subunit gene, suitable for diagnosis and treatment of integrin ligand mediated diseases
AU5550800A (en) Diagnosis and treatment of alzheimer's disease
AU4654500A (en) Prevention, diagnosis and treatment of lyme disease
AU5876399A (en) Polymorphisms in the human beta1 integrin subunit gene, suitable for diagnosis and treatment of integrin ligand mediated diseases
AU1774299A (en) Polymorphisms within the rsk-3 gene related to cancer and methods of diagnosis, prognosis, and treatment
AU2003245858A1 (en) Uses of ngal-binding substances in the diagnosis and treatment of cancer diseases
AU5875599A (en) Polymorphisms in the human vcam-1 gene, suitable for diagnosis and treatment of vcam-1 ligand mediated diseases
AU5618700A (en) Extracellular camp-dependent protein kinase in diagnosis, prognosis and treatment of cancer
WO2001011039A3 (fr) Nouveaux variants de sequences du gene humain de l'adrenorecepteur $g(b)1
NZ513739A (en) Cloning of cDNA of mage's 5, 8, 9 and 11 and their uses in diagnosis of cancer

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase